Study of Varespladib in Patients Hospitalized With Severe COVID-19

Stopped Part 2 of the study was paused on 03-May-2022 due to slow enrollment following low infection rates and hospitalizations of patients with severe COVID-19, and did not recommence prior to study closure (early termination) on 22-Nov-2022.

Conditions

• Coronavirus Disease 2019
• Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

• DRUG: Varespladib
• DRUG: Placebo

Sponsor

Ophirex, Inc.

Collaborators

• [object Object]